# Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

> **NCT02165397** · PHASE3 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 181 (actual)

## Conditions studied

- Waldenström's Macroglobulinemia

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Placebo
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02165397
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-07
- **Primary completion:** 2019-11-07
- **Final completion:** 2019-11-07
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2021-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02165397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02165397, "Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02165397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*